Vertex Pharmaceuticals Stock Soaring: Is More Upside Ahead?
Vertex Pharmaceuticals has climbed to fresh highs, fueled by a robust cystic fibrosis portfolio and strong cash flow....
Risk parity assigns capital to balance risk contributions across asset classes in retirement portfolios, aiming for steadier, more resilient returns.
26,821 articlesVertex Pharmaceuticals has climbed to fresh highs, fueled by a robust cystic fibrosis portfolio and strong cash flow....
The Metals Company stock faced a sharp pullback in early 2026 after a dramatic rally in the previous year. This artic...
A major insider move is lighting up the markets as Fluor dumps million shares of NuScale SMR for $1.35 billion. Here’...
A fictional scenario examines a potential shareholder class-action targeting coinbase brian armstrong execs over cust...
On Tuesday, a leading critical metals stock surged on news before cooling later in the day. This piece explores what ...
A biotech stock surged 75% last quarter and drew a new $9 million investment, signaling confidence from sophisticated...
Can Trump Media outpace the broader market? This in-depth analysis breaks down the business model, risks, and the sig...
A Brazilian fund made a sizable bet on MercadoLibre even as the stock slid over the past year. This article unpacks t...
Canopy Growth has slipped while the market rose. This article breaks down the reasons behind the drop, what it means ...
When a stock seems to leap higher ahead of the broader market, investors ask: what's behind the move? This guide uses...
Nebius stock has drawn attention for rapid AI cloud growth, but two core risks could derail momentum. This guide give...
SpaceX's IPO hype is hard to ignore, but there are four solid concerns investors should weigh before buying in. This ...